

## Electronic Supplementary Information

### Does conjugation strategy matter? Cetuximab conjugated gold nanocages for triple negative breast cancer cells targeting

S. Avvakumova,<sup>a</sup> L. Pandolfi,<sup>b</sup> E. Soprano,<sup>a</sup> L. Moretto,<sup>a</sup> M. Bellini,<sup>a</sup> E. Galbiati,<sup>a</sup> M. A. Rizzuto,<sup>a</sup> M. Colombo,<sup>a</sup> R. Allevi,<sup>c</sup> F. Corsi,<sup>c,d,e</sup> A. Sánchez Iglesias,<sup>f</sup> and D. Prosperti<sup>\*a</sup>

---

<sup>a</sup> University of Milano "Bicocca", Department of Biotechnology and Bioscience, Piazza della Scienza, 2, 20126, Milano, Italy


<sup>b</sup> Clinica di Malattie dell'Apparato Respiratorio, IRCCS Fondazione Policlinico San Matteo, Pavia, Italy

<sup>c</sup> Dipartimento di Scienze Biomediche e Cliniche "Luigi Sacco", Università di Milano, via G.B. Grassi 74, 20157 Milano, Italy

<sup>d</sup> Surgery Department, Breast Unit, ICS Maugeri S.p.A. SB, via S. Maugeri 10, Pavia, Italy

<sup>e</sup> Nanomedicine Laboratory, ICS Maugeri S.p.A. SB, via S. Maugeri 10, Pavia, Italy


<sup>f</sup> CIC BiomaGUNE and CIBER-BBN, Paseo de Miramón 182, 20014 Donostia-San Sebastián, Spain




**Figure S1.** Au-SugOX NCs preparation *via* sugar moiety oxidation of CTX.

**Table S1.** SPR band maxima of AuNPs before functionalization (AuNCs<sup>1</sup> and AuNCs<sup>2</sup>) and after functionalization with CTX. SPR peaks shift after functionalization. Numbers <sup>1</sup> and <sup>2</sup> represent two different batches of starting nanoparticles, showing that SPR shift is independent of the batch used.

Sample	SPR peak, nm	$\delta$ (SPR), nm
AuNCs <sup>1</sup>	732 nm	--
AuNCs <sup>2</sup>	756 nm	--
OPEG CTX <sup>2</sup>	772 nm	16 nm
spa-CTX <sup>1</sup>	744.5 nm	12.5 nm
spa-CTX LINKER <sup>1</sup>	748 nm	16 nm
HC CTX <sup>1</sup>	749 nm	17 nm
HC CTX LINKER <sup>1</sup>	748 nm	16 nm




**Figure S2.** UV-vis spectra of starting AuNCs, Au-OPEG-CTX, Au-spa-CTX and Au-HC-CTX after conjugation with CTX.




**Figure S3.** UV-vis spectra of starting AuNCs, AuNCs PEGylated with HS-PEG<sub>3000</sub>-NH<sub>2</sub> (Au-PEG-NH<sub>2</sub>), and functionalized with CTX with oxidized saccharide moiety (Au-SugOX-CTX).

**Table S2.** Dynamic light scattering and zeta potential values of CTX conjugated AuNCs.


Sample	Number mean, nm	PdI	Z-Pot, mV
Au-PVP	53.87±3.77	0.144±0.011	-26.0±2.7
Au-OPEG-CTX	63.36±1.89	0.170±0.006	-19.7±0.8
Au-spa-CTX	55.52±3.61	0.154±0.008	-19.3±1.6
Au-linker-spa-CTX	68.03± 3.423	0.164± 0.016	-25.9± 0.231
Au-HC-CTX	84.65±8.69	0.173±0.014	-16.7±0.3
Au-linker-HC-CTX	59.79± 5.28	0.219± 0.009	-22.8± 0.141



**Figure S4.** Colloidal stability of nanoparticles in PBS pH 7.5, NaCl 150 mM, carbonate buffer pH 8.5, and FBS: a) Au-PVP (756 nm SPR), b) Au-PVP (732 nm SPR), c) Au-OPEG-CTX, d) Au-spa-CTX, e) Au-HC-CTX, f) Au-spa-linker-CTX, and g) Au-HC-linker-CTX.



**Figure S5.** Cellular uptake of AuNCs conjugated with CTX by different conjugation approaches in 3T3-L1 cells. Gold content per cell was analysed by ICP-AES, and number of NPs per cell was calculated. 0.4 and 0.8 nM concentration of nanoconjugates was used for the experiments.



**Figure S6.** Cellular binding and uptake of Au-OPEG-CTX and Au-spa-CTX nanoconjugates at 4 and 37 °C in 3T3-L1 cells, in presence and absence of free CTX.